As of August 1, myotwin GmbH has expanded its presence by moving into office space at the Rechtsrheinisches Technologie- und Gründerzentrum Cologne (RTZ). With this step, the biotech start-up continues to grow its business activities while strengthening its integration into Cologne’s high-tech ecosystem.
The RTZ provides young technology companies in their early stages with office and laboratory space, fully equipped seminar and meeting rooms, business support services, and access to an extensive network. As an incubator, it helps founders bring their ideas to life and lays the foundation for sustainable growth. Currently, around 40 companies form a vibrant […]
For the second time, myotwin GmbH participated in the BIO International Convention, the world’s largest trade fair for biotechnology and pharmaceuticals.
For the myotwin team, the convention was more than just an industry gathering – it was a valuable opportunity to present its technology platform for the development of new cardiovascular therapeutics on an international stage and to further expand its network. The focus was on intensive discussions with potential partners from pharma and biotech – […]
myotwin GmbH looks back on a successful participation at this year’s International MPS Society (iMPSS) conference in Brussels.
The international forum, organized by EUROoCS and the International MPS Society, brought together leading scientists, industry representatives, and patient groups to discuss the latest developments in mucopolysaccharidosis (MPS) and related diseases. A particular highlight was myotwin’s poster presentation “Heart Attack in a Dish.” The model, which replicates cardiovascular disease mechanisms at the cellular level, attracted […]
The biotech start-up myotwin GmbH has successfully completed the EXIST Research Transferprogram. With funding from the Federal Ministry for Economic Affairs and Energy (BMWE), the foundation for the company spin-off was established and its technology platform significantly advanced.
Following the completion of Phase I (Sept. 2022–Aug. 2024), carried out by the University Medical Center Göttingen, Phase II was implemented by myotwin GmbH and ran until the end of March 2025. “We are very grateful for the support provided through the EXIST Research Transfer. It paved the way for us to bring our technology […]
The biotech start-up myotwin GmbH and the data management company IndiScale GmbH are launching a joint project to optimize the production of artificially generated human mini-organs using artificial intelligence.
Artificial Organs for Heart Research The artificial production of heart muscle tissue offers a promising approach for the development of new drugs against cardiovascular diseases, which are the leading cause of death worldwide. The project “AI-based Optimization of the Production of Cardiac Bodies” aims to make the production process of Cardiac Bodies – a precursor […]
Three days filled with discussions, meetings, and fresh inspiration: myotwin GmbH took part in BIO-Europe Spring 2025 in Milan and draws a thoroughly positive conclusion. The conference is one of the leading meeting points for the European biotech and pharma community and once again offered a dynamic environment for exchange and collaboration.
For the myotwin team, networking with industry partners was at the forefront. Numerous encounters with representatives from both industry and the start-up scene opened up new perspectives and confirmed myotwin’s growing role within the international biotech ecosystem. A particular highlight was reconnecting with colleagues from the EXIST funding program, including the team from immuneAdvice GmbH. […]
myotwin GmbH has successfully completed the HTI funding program of the State of Lower Saxony. The €200,000 funding project was coordinated through the Life Science Valley in Göttingen and enabled myotwin to successfully launch its business operations.
With the funding, the company was able to establish laboratory infrastructure in the Life Science Factory in Göttingen, hire its first scientific staff, and validate key technologies for the planned platform. This laid the foundation for preparing initial pilot studies with partners from the pharmaceutical and biotech industries and paved the way for market entry. […]
myotwin GmbH looks back on a successful participation at the 30th BIO-Europe in Stockholm. From November 4 to 6, 2024, the event brought together more than 5,500 professionals from over 2,800 companies and more than 60 countries.
myotwin was represented on site by co-founder Andreas Meyer-Borgstädt. For the company, the conference offered a valuable opportunity to engage with partners from pharma and biotech, establish new contacts, and expand existing networks. Compared to previous events, the growing importance of artificial intelligence emerged as a key theme in many discussions. With numerous promising conversations […]
myotwin GmbH participated in this year’s BIO International Convention in San Diego. With more than 19,500 attendees from 70 countries, 1,400 exhibitors, and over 61,000 partnering meetings, the event set new records and reaffirmed its position as the world’s largest biotechnology gathering.
For myotwin, the convention offered a unique opportunity to present its platform of human-based cardiac tissue models in an international context and to engage directly with industry partners and experts. Discussions were particularly shaped by open dialogue on the future of drug development, strategies to reduce animal testing, and new partnership models. Beyond the intensive […]
myotwin GmbH participated in this year’s BIO-Europe in Munich, one of Europe’s leading conferences for the biotechnology and pharmaceutical industries. Over several days, the team took the opportunity to exchange ideas with industry partners and present its platform.
myotwin’s approach of reducing animal testing through realistic human-based models attracted significant attention. The company was represented at BIO-Europe for the first time with its own booth, providing an ideal opportunity to introduce itself to the European biotech community just a few weeks after its founding. With numerous new contacts, promising discussions, and a very […]